Creating New Dimensions
About Triastek
Global leader in 3D printing pharmaceuticals
Pioneer of new digital pharmaceutical processes
Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medicines through digital product development and continuous manufacturing.
Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals.
Our vision is to become the world's most influential intelligent pharmaceutical enterprise.
Global leader in 3D printing pharmaceuticals
Pioneer of new digital pharmaceutical processes
Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide...
Last updated: November 2024
248
Patent
Applications
91
Granted
Patents
12
Territories
Melt Extrusion Deposition
3D Printing Process
Melt Extrusion Deposition (MED®) 3D printing is a process that continuously converts powder feedstocks into softened/molten states followed by precise layer-by-layer deposition to produce objects with well-designed geometric structures.
Business Model
Triastek’s 3D Microstructure Delivery Technology Platform
Triastek has developed multiple 3D microstructure delivery technology platforms that enable precise control when, where and how much medicine is released in the body, allowing for unlimited possibilities in the creation of solid dosage forms.
Triastek has completed 70+ novel dosage form designs and 10+ human data validations.
3DμS®-MR
3D Microstructure for Modified Release
3DμS®-SE
3D Microstructure for Solubility Enhancement
3DμS®-CT
3D Microstructure for Colon Targeting
3DμS®-GR
3D Microstructure for Gastric Retention
3DμS®-OP
3D Microstructure for Oral Peptide
Pipeline
RA: Rheumatoid Arthritis; PsA: Psoriatic Arthritis; AS: Ankylosing Spondylitis; AF: Atrial Fibrillation; VTE: Venous Thromboembolism; UC: Ulcerative Colitis; PAH: Pulmonary Arterial Hypertension; IgAN: IgA nephropathy
BD@triastek.com
苏ICP备17053162号 苏公网安备 32011502011777号
All Rights Reserved
Copyright © 2024 (TRIASTEK)
Contact Us
BD@triastek.comCOPYRIGHT © 2024 TRIASTEK. 苏ICP备17053162号
DIGITAL By VTHINK